Tumor proliferation in squamous cell carcinoma of the vulva

International Journal of Gynecological Pathology

Volumn 19, Issue 4, 2000, Pages 361-368

  Hantschmann, P ^a   Lampe, B ^a   Beysiegel, S ^a   Kurzl, R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Ki 67; MIB 1; Squamous cell carcinoma; Vulva

Indexed keywords

ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR GROWTH; VULVA CARCINOMA;

EID: 0033739797     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200010000-00011     Document Type: Article

References (38)

1. Individualized treatment of stage I carcinoma of the vulva
2. Stage I squamous cell cancer of the vulva
3. Operative management of early invasive epidermoid carcinoma of the vulva
4. Infiltrative carcinoma of the vulva: Results of surgical treatment
5. Prognostic factors in epidermoid carcinoma of the vulva
6. Squamous cell carcinoma of the vulva: Prognostic factors influencing survival
7. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study)
8. Prognostic significance of lymph node variables in squamous cell carcinoma of the vulva
9. Prognostic value of pathological patterns of lymph node positivity in squamous cell carcinoma of the vulva stage III and IVA FIGO
10. Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma
11. Prognostic significance of nucleolar organizing regions (NORs) in carcinomas of the sigmoid colon and rectum
12. AgNOR counts and histological grade in stage pTa bladder tumours: Reproducibility and relation to recurrence pattern
13. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
14. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
15. Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki-67 protein)
16. Growth fractions in gastric carcinomas determined with monoclonal antibody Ki-67
17. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas
18. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel 'paraffin'-reactive MIB1 antibody
19. Use of flow cytometry in the analysis of stage III squamous cell carcinoma of the oesophagus and its association with MIB-1
20. Quantitation of proliferation-associated markers Ag-NOR and Ki-67 does not contribute to the prediction of lymph node metastases in squamous cell carcinoma of the vulva
21. Ki-67 expression in vulvar carcinoma
22. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva
23. S-Phase fraction, p53, and HER-2/neu status as predictors of nodal metastasis in early vulvar cancer
24. Histologic malignancy grading in invasive squamous cell carcinoma of the vulva
25. Microinvasive carcinoma of the vulva
26. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors
27. The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract
28. Ki-67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis
29. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer
30. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study
31. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma
32. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices
33. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer
34. Microinvasive carcinoma of the vulva: A clinicopathologic evaluation
35. Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma
36. Immunohistological detection of nm23-H1 protein in vulvar squamous cell carcinoma
37. Expression of tumor proteases cathepsin-D and pro-cathepsin-L in squamous cell carcinoma of the vulva
38. Basaloid and warty carcinomas of the vulva: Distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses